Chongqing Yuyan Pharmaceutical Co., Ltd. announced that it has received CNY 300 million in an equity round of funding on November 15, 2023. The transaction included participation from new investors, Huadong Medicine Co., Ltd, Hangzhou State Capital Investment And Operations Co., Ltd. and Hangzhou Gongshu State Investment Industry Development Co., Ltd. for 8.57140% stake.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
32.21 CNY | -0.77% | +2.81% | -22.31% |
01:00am | Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic | RE |
01:00am | Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.31% | 7.78B | |
+25.19% | 75.34B | |
-2.82% | 23.86B | |
+9.05% | 8.61B | |
+10.64% | 8.52B | |
+11.90% | 5.18B | |
+1.86% | 4.13B | |
-5.04% | 4.03B | |
+3.71% | 3.82B | |
+21.59% | 3.62B |
- Stock Market
- Equities
- 000963 Stock
- News Huadong Medicine Co., Ltd
- Chongqing Yuyan Pharmaceutical Co., Ltd. announced that it has received CNY 300 million in funding from Huadong Medicine Co., Ltd, Hangzhou State Capital Investment And Operations Co., Ltd., Hangzhou Gongshu State Investment Industry Development Co., Ltd.